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The adenovirus immediate-early protein EIA activates the adenovirus E2 promoter and several cellular gene
promoters through transcription factor E2F. The immediate-early proteins of human cytomegalovirus
(HCMV) can complement an ElA-deficient adenovirus mutant and activate the adenovirus E2 promoter.
HCMV also has been shown to activate the adenovirus E2 promoter. On the basis of these findings, we have
investigated whether HCMV can activate the promoter of the cellular dihydrofolate reductase (DHFR) gene,
which requires E2F binding for maximal promoter activity. We show that HCMV activates the DHFR
promoter and that products of the HCMV major immediate-early gene region mediate the activation of the
promoter specifically through the E2F site. We used gel mobility shift assays to search for potential molecular
mechanisms for this activation and found an "infection-specific" multimeric complex that bound to the E2F
sites in the DHFR and E2 promoters in extracts from HCMV-infected cells but not in extracts from uninfected
cells. Several antibodies against HCMV immediate-early gene products had no effect on this infection-specific
complex. Subsequently, the complex was found to contain E2F, cyclin A, p33Cdk2, and p107 and to be similar
to S-phase-specific complexes that recently have been identified in several cell types. A functional role for the
binding of the cyclin A-p33Cdk2 complex to cellular gene promoters has yet to be demonstrated; however,
HCMV infection causes the induction of both cellular DNA replication and transcription of growth-related
genes containing E2F sites in their promoters. The findings described above therefore may relate to both of
these effects of HCMV infection. We also provide evidence that some of the molecular events associated with
adenovirus infection are different from those associated with HCMV infection.
Transcription factor E2F, first identified as a HeLa cell
factor that binds to the adenovirus E2 promoter, has since
been implicated in viral modulation of the expression of
several cellular growth-controlled genes (41, 43, 58, 86).
Recent studies of E2F have focused on its association in
multimeric DNA binding complexes with other cellular
proteins at specific times during the cell cycle. For example,
E2F associates with the underphosphorylated Gl form of
tumor suppressor protein Rb in a complex that appears to
down-regulate transcription (9, 19-21, 42, 78). Other studies
have revealed in several cell types an S-phase-specific
complex that includes at least four proteins: E2F, retinoblas-
toma-related protein p107, cyclin A, and a cyclin A-regu-
lated protein serine-threonine kinase, p33cdk2 (for "cyclin-
dependent kinase" or "cell division kinase"), that is
homologous to another cyclin-regulated master cell cycle
kinase, p34cdc2 (19, 24, 28, 30, 65, 69, 78). There has also
been a report that both cyclin A and Rb are components of
a DNA binding complex with an E2F-like activity, termed
DRTF-1 (10). Although the E2F-p107-cyclin A-cdk2 com-
plex has been shown to have histone kinase activity in vitro
(24), an in vivo role for E2F-associated kinase activity has
not been demonstrated.
Among the cellular gene promoters modulated by E2F is
that of dihydrofolate reductase (DHFR). The DHFR enzyme
* Corresponding author.
is required for DNA synthesis because it provides reduced
folates in the biosynthetic pathways for nucleotides. A
previous study of the hamster DHFR promoter demon-
strated that E2F, which binds to an overlapping dyad se-
quence element just downstream of the major transcription
start site, is required for maximal basal transcription (14).
Another required factor is Spl, an abundant and well-
characterized mammalian protein that binds to four up-
stream GC-rich elements in the hamster DHFR promoter
(14, 15, 83).
Because of the demonstrated ability of human cytomega-
lovirus (HCMV) to induce the transcription of cellular genes
associated with DNA replication, we examined the activa-
tion of the DHFR promoter and binding to the DHFR E2F
site during infection by HCMV. There were several reasons
to suspect that E2F could be involved in the cellular re-
sponse to HCMV. First, previous work showed that imme-
diate-early (IE) proteins of HCMV can complement an
ElA-deficient adenovirus mutant and induce transcription
from the adenovirus E2 early promoter (40, 79, 85). In
addition, we noted potential E2F binding sites in regions of
the promoters of at least three HCMV early genes that are
important for transactivation by HCMV IE protein(s) during
a productive viral infection (54, 55, 62, 80, 89). Finally, the
recently discovered association of E2F with proteins linked
to cell cycle control implied that HCMV, a potentially
transforming herpesvirus that activates cellular DNA syn-
thesis and proliferation, could act to alter the interactions
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among E2F and other proteins (4, 5, 23, 32, 81, 82; reviewed
in reference 2).
Previous work had shown that adenovirus stimulates E2F
binding activity, dependent on the expression of the viral
ElA protein. The formation and functional role of an E1A-
dependent heteromeric complex containing E2F and the
viral E4 protein on the adenovirus E2 early promoter have
been investigated extensively. However, adenovirus activa-
tion of cellular promoters through E2F apparently does not
involve the formation of heteromeric complexes but instead
is associated with an induction of the binding activity of free
E2F-that is, E2F that is not complexed with another
protein (7, 41, 74, 86).
Despite the apparent functional similarities between ade-
novirus ElA and HCMV IE protein(s), there has not been a
study of the specific role of E2F in the HCMV activation of
gene promoters, nor has there been an examination of E2F
binding activity during an HCMV infection. We report here
that HCMV activates the DHFR promoter and that the
activation can be mediated through the E2F site by viral IE
gene products. Furthermore, we show that HCMV infection
is associated with the formation of an E2F-containing heter-
omeric complex that is dependent on a single E2F recogni-
tion sequence. We have termed this complex "infection
specific" throughout this report, but our results indicate that
the four known components of the HCMV-induced com-
plex-E2F, cyclin A, p33cdk2, and p107-are also part of a
complex that binds specifically to E2F sites during the S
phase of the cell cycle. These findings implicate a cellular
transcription factor as a target for HCMV activation and
may relate to earlier reports that HCMV stimulates cellular
DNA synthesis and proliferation (4, 23, 81, 82).
(M.W. performed this work in partial fulfillment of the
requirements for a Ph.D. degree from the Curriculum in
Genetics, University of North Carolina, Chapel Hill.)
MATERIALS AND METHODS
Cell culture and nuclear extract preparation. Newborn
human foreskin fibroblast (NHF) cells were kindly provided
by W. Kaufman (University of North Carolina, Chapel Hill).
NHF, Cos-1, and human embryonic lung (HEL) cells were
cultured in Eagle's minimal essential medium supplemented
with 10% fetal bovine serum (GIBCO) and penicillin-strep-
tomycin. NHF and HEL cell nuclear extracts were prepared
as described previously (14, 25), except that cells were
mechanically scraped from monolayer cultures in Ca- and
Mg-free Hanks balanced salt solution plus 25 mM EDTA.
For synchronization experiments, HEL cells in mid-log
phase were serum starved for 36 h by reducing the medium
supplement to 0.5% calf serum. Serum was added to starved
cells to a final concentration of 20%, and S-phase extracts
were prepared 18 h later.
V'irus infections. HCMV Towne strain (passage 37) stocks
were prepared as described previously (48). Virus was added
to NHF or HEL cells (80% confluence) at a multiplicity of
infection of 5 and adsorbed for 2 h. Infecting fluids contain-
ing no virus particles were added to uninfected or mock-
infected cells.
Gel mobility shift assays. Gel mobility shift assays were
performed essentially as described previously (43). The
reaction mixture contained 0.1 to 0.5 ng of labeled DHFR or
E2 promoter fragment in 20 ,ul of binding reaction buffer (20
mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
[HEPES] [pH 7.8], 1 mM MgCl2, 0.1 mM EDTA, 40 mM
KCI, 0.5 mM dithiothreitol, 2 pg of salmon sperm DNA, 60
,ug of bovine serum albumin, 1.5% Nonidet P-40 [Sigma], 1%
Ficoll) and 3 to 15 ,ug of nuclear protein. For deoxycholate
(DOC) dissociation experiments (12), Nonidet P-40 was left
out of the reaction buffer until the reaction mixture had been
incubated in the presence of DOC (final concentration,
0.25%) for 10 to 15 min, after which Nonidet P-40 was added
to a final concentration of 1.5%. When needed, antibodies or
antisera were added to the reaction mixture in the presence
of cell extract, and a labeled DNA probe was added imme-
diately afterward. Binding reactions proceeded at room
temperature or at 4°C, and gels (4% polyacrylamide; acryl-
amide-bisacrylamide, 29:1) were run for 60 to 80 min at 4°C
before being dried and autoradiographed.
In vitro translation of E1A. Plasmids encoding the wild-
type and 928 point mutant 12S ElA proteins (73) were
transcribed in vitro with SP6 polymerase and capped before
in vitro translation with a reticulocyte lysate kit (Promega
Biotec) as described previously (65, 73). The amounts of
translation products were quantitated by parallel translation
reactions in the presence of [35S]methionine and then sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and au-
toradiography of dried gels. Aliquots from unlabeled trans-
lation reaction mixtures containing equal amounts of wild-
type or mutant 12S ElA protein were added to gel mobility
shift reaction mixtures.
Antisera and antibodies. Rabbit antiserum against cyclin A
was provided by J. Pines and T. Hunter (72). Another
anti-cyclin A rabbit antiserum and affinity-purified rabbit
antibodies against p107 were a gift from J. Schwarz. Rabbit
antisera against p34cdc2 and p33cdk2 were provided by M.
Pagano and P. Jansen-Durr (69, 70). Mouse antiserum
against p33cdk (87) and monoclonal antibody XZ77, which
recognizes Rb but not p107 (45), were gifts from Ed Harlow.
Polyclonal antibodies against HCMV major IE gene region
products were provided by R. Jupp and J. Nelson, and an
anti-HCMV IE 1 and 2 monoclonal antibody was obtained
from Dupont (catalog no. 9221). Affinity-purified rabbit
antibodies against cyclin B and p34cdc2 and additional anti-
bodies against Rb were purchased from Oncogene Science.
Transient expression assays. NHF cells were transfected
by the calcium phosphate method (35). Cos-1 cells were
transfected with Lipofectin (BRL) in accordance with the
manufacturer's protocol. In each case, cells were trans-
fected at 30 to 50% confluence. In all chloramphenicol
acetyltransferase (CAT) assay experiments, the total amount
of cotransfected DNA was normalized with pUC18. Cells
were harvested at various times and lysed by repeated
freezing-thawing, and clarified supernatants were assayed
for CAT activity (34). Levels of activity were quantitated by
liquid scintillation counting of [14C]chloramphenicol con-
verted to acetylated forms after autoradiography of thin-
layer chromatography plates.
Plasmids. A plasmid expressing the HCMV IE 1 and 2
genes under the control of the HCMV major IE promoter
(pHD1O1SV1) (22) was modified by removal of a 1.1-kb
HindIII restriction fragment containing the simian virus 40
early promoter-enhancer region. The wild-type, single-site
mutant, and double-site mutant DHFR-CAT expression vec-
tors were described previously (14, 41) and are shown
diagrammatically in Fig. 1A. The pE2-CAT expression vec-
tor was described previously (59). Plasmids containing the
DHFR wild-type and double-site mutant E2F sites were
described earlier (14). A plasmid containing the DHFR
single-site mutant E2F site was created by site-directed
mutagenesis (56) of plasmid pDHF-239 (83) with a mutagenic
oligonucleotide described previously (43). For removal of
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Adenovirus E2 WT site
Adenovirus E2 single site
DHFR overlapping dyad site
DHFR single site (2) mutant
CCCGACTGCAATTTCGCGCCAAACTTGGG
CCCGACTGCAATTTCGATCCAAACTTGGG
DHFR E2F WT probe
DHFR E2Fdsmut probe
CCCGACTGCAATTTCGCGCCTTTCTTGGG DHFR E2F Site 2 mut probe
FIG. 1. Promoter constructs and oligonucleotides. (A) Diagram of the wild-type hamster DHFR promoter-CAT construct showing the
sequence elements that have been shown to bind cellular transcription factors. These include GC boxes I, II, III, and IV (stippled boxes) and
the overlapping dyad E2F site (cross-hatched box). The major (large arrow) and minor (small arrow) transcription start sites are shown.
Numbering is relative to the translation start site, which is +1. (B) Configuration of E2F sites to which E2F binds in wild-type (WT) and
mutant adenovirus E2 and DHFR promoters. The adenovirus E2 promoter E2F sites are 16 bp apart and oppositely oriented. The DHFR
promoter E2F sites also are oppositely oriented, as shown, but share 4 bp in an overlapping region. Site 1 is the 5' site on the top strand, while
site 2 is the 3' site on the bottom strand. The single-site (site 2) mutant used in some experiments contains only the 5' binding site and contains
a mutation of the 3' site identical to that shown for the site 2 mutant (mut) oligonucleotide. (C) Oligonucleotide sequences. A double point
mutation, CG to TA, abolishes both DHFR E2F sites in the E2F double-site mutant (E2Fdsmut) probe, to which E2F does not bind. A triple
point mutation, AAA to T1T, abolishes the 3' E2F site in the site 2 mutant probe, but E2F still binds to the 5' E2F site.
the upstream GC boxes, a HindIII-HaeIII fragment contain-
ing the single-site mutant E2F site was subcloned into
pUC18 cut with HindIII and HincII. Appropriate restriction
fragments were labeled with the Klenow fragment, [32p]
dATP, and/or [32P]dCTP.
Methylation interference and missing base contact assays.
Partially methylated (at G residues) or depyrimidinated
DNA was prepared by treatment of end-labeled probes with
dimethyl sulfate or hydrazine, respectively, as described
previously (64). The modified probes were added to prepar-
ative gel mobility shift reaction mixtures. DNA binding
complexes and free probes were resolved by electrophoresis
and autoradiography, excised from gels, and eluted in a
buffer consisting of 10 mM Tris (pH 8.0)-10 mM EDTA-0.2
M NaCl. The labeled probes were purified through a 0.45-
,um-pore-size Acrodisc filter (Gelman Sciences), loaded onto
an Elutip column (Schleicher and Schuell), and eluted from
the column with 1.0 M NaCl-10 mM Tris (pH 8.0)-10 mM
EDTA before ethanol precipitation. The modified probes
were cleaved with piperidine and loaded onto denaturing
polyacrylamide gels.
RESULTS
Figure 1A shows a schematic diagram of the hamster
DHFR promoter-CAT construct used to assess activation by
HCMV infection or by HCMV IE gene products. The E2F
site and the three promoter-proximal GC boxes are required
for maximum basal transcription and transient expression
from the promoter, as determined by previous studies (14,
15, 83). The major and minor transcription start sites, as
demonstrated by primer extension analysis (15), are shown.
The E2F double-site mutant promoter used for these assays
is identical to this construct, except for a double point
mutation that abolishes E2F binding to the site (14); this
promoter mutation, CG to TA, is the same as that shown in
the DHFR double-site mutant oligonucleotide (Fig. 1C). The
DHFR site 2 mutant promoter is identical to the wild-type
promoter, except for a triple point mutation that abolishes
the 3' E2F site in the overlapping dyad (lTllTCGCGCCAAA)
but leaves the 5' E2F site intact; the sequence of this mutant
is ll7ITCGCGCCTiJl[ (underlining indicates the mutation).
The configurations of E2F sites on the wild-type and
mutant DHFR and E2 promoter fragments used in gel
mobility shift assays are shown in Fig. 1B. Other factor
binding sites on the promoters (the DHFR promoter GC
boxes and the E2 promoter ATF site) are not included in
these fragments. The mutation creating the E2 single-site
mutant sequence was described previously (59). The se-
quences of the oligonucleotides used as competitors in the
binding assays are shown in Fig. 1C; the double-site muta-
tion, TlTCGT[ACCAAA, abolishes E2F binding.
HCMV activation of the DHFR promoter. HCMV can
complement an ElA-deficient adenovirus mutant, and acti-
vation of the adenovirus E2 promoter is efficiently mediated
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FIG. 2. (A) E2F binding mediates activation by IE gene prod-
ucts. NHF cells were transfected with 5 p.g of a construct containing
either the wild-type (WT) or the double-site mutant (dsmut) DHFR
promoter linked to a CAT reporter. Cells were cotransfected with 0,
0.1, or 1.0 pg of an HCMV IE 1 and 2 expressor plasmid; the total
amount of cotransfected DNA was adjusted to 1.0 p.g with pUC18.
Cells were harvested 48 h after transfection and analyzed for CAT
activity. (B) A single E2F site is sufficient for IE activation. Cos-1
cells were transfected with 5 ,g of a construct containing the
wild-type, double-site mutant, or single-site mutant (ssmut) DHFR
promoter linked to a CAT reporter. Cells were cotransfected with
either 0 or 0.1 ,ug of a plasmid expressing the HCMV IE 1 and 2 gene
products.
adenovirus ElA protein activates the DHFR promoter in an
E2F-dependent manner (41). We first confirmed that HCMV
infection activates an adenovirus E2 promoter-CAT con-
struct and determined that a wild-type DHFR promoter-
CAT construct was also efficiently activated by HCMV
infection (data not shown). We then asked whether HCMV
IE 1 and 2 gene products could mediate trans-activation of
the DHFR promoter and whether the E2F site was involved
in the activation. Figure 2A shows the result of an experi-
ment in which either a control plasmid or the indicated
amounts of a plasmid expressing the IE 1 and 2 genes (22)
were cotransfected into NHF cells along with a wild-type or
E2F double-site mutant DHFR promoter-CAT construct.
The wild-type promoter efficiently activated the reporter
gene, while little activation was observed in the absence of a
functional E2F site.
The experiment depicted in Fig. 2B shows the effects of IE
1 and 2 gene products on expression from the wild-type
DHFR promoter and on two E2F site mutant promoters in
Cos-1 cells. The wild-type DHFR promoter and the single-
site mutant promoter in which one of the two E2F sites was
abolished (Fig. 1B) were efficiently activated by the IE 1 and
2 gene products. However, equivalent amounts of the plas-
mid expressing IE 1 and 2 gene products failed to activate
the double-site mutant promoter, to which E2F does not
bind. This result demonstrates that E2F can mediate trans-
activation of the DHFR gene by HCMV IE 1 and 2 gene
products.
Changes in E2F binding activity after HCMV infection.
Previously, gel mobility shift assays were used to examine
binding to the E2F site of the DHFR promoter in the
presence of extracts from HeLa cells (14). To assess the
effect of HCMV infection on protein-DNA interactions at
the DHFR E2F site, we initially performed gel mobility shift
assays using extracts from uninfected NHF cells and from
NHF cells harvested 12, 40, and 65 hours postinfection (hpi).
The probes for these assays were promoter fragments that
contained the wild-type or single-site (site 2) mutant DHFR
E2F site or a 29-mer oligonucleotide containing the wild-type
DHFR E2F site. Identical gel mobility shift patterns were
obtained with each of these probes; furthermore, the pat-
terns of binding in these extracts to E2 promoter fragments
containing either one or both E2F sites (Fig. 1B) were also
identical (data not shown). These findings demonstrated that
a single E2F site, lTTlCGCGC, is sufficient for binding and
are consistent with the data demonstrating that a single E2F
site confers responsiveness to HCMV IE gene products. The
results shown in Fig. 3A were obtained with the promoter
fragment containing the wild-type DHFR E2F site. In re-
peated experiments, we observed in uninfected-cell extracts
a band that migrated with previously characterized free E2F
in HeLa cells. This form of E2F is apparently not complexed
with other proteins (8, 14). Additionally, we observed in
uninfected-cell extracts a more slowly migrating band (lanes
2 and 9) that decreased in intensity after viral infection. This
complex may be analogous to a Gl-specific complex that has
been observed by others (65, 66, 77) and was further
characterized (see Fig. 5).
The most striking change observed in E2F binding after
infection was the induction of a complex (marked by an
arrowhead adjacent to Fig. 3A, lane 4), which we termed
infection specific, in extracts from NHF cells harvested 40
hpi. A more slowly migrating binding activity also was
increased in some experiments, but this activity was ob-
served only in NHF cell extracts, was not always reproduc-
ible, and was not specific for the E2F site (Fig. 3A, lanes 6 to
8). By 65 hpi, all E2F binding activity was markedly re-
duced; the reason for this is at present unclear. The different
E2F complexes obtained with the E2F site probes at differ-
ent times were not caused simply by variability in the protein
quality or DNA binding activity of the extracts, as a control
experiment shown in Fig. 3B demonstrates. Binding to a
probe containing the recognition sequence for the adenovi-
rus major late transcription factor (MLTF) was not different
among these extracts (Fig. 3B, lanes 2 to 5).
In subsequent experiments, we tested E2F binding in
mock-infected and HCMV-infected HEL cells. In some
experiments, these cells allowed us to resolve more sharply
defined complexes, perhaps because of less proteolytic
activity, and the infection-specific complex appeared earlier
during infection (by 4 hpi). Otherwise, the corresponding
complexes observed in HEL cell extracts were identical, by
all criteria tested (see below), to those observed in extracts
from NHF cells. The DNA binding complexes observed in
mock-infected and 4-hpi HEL cell extracts are shown in Fig.
3A, lanes 9 and 10, respectively. These results and similar
data obtained with a DHFR E2F single-site mutant probe
demonstrated that HCMV infection led to an infection-
specific DNA binding activity that appeared to be mediated
by a single E2F site.
Characterization of the HCMV infection-specific complex.
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FIG. 3. (A) Protein-DNA complex induced by HCMV infection.
Lane 1 (FP) shows the migration of a labeled DHFR promoter
fragment incubated in gel mobility shift reaction buffer in the
absence of a cell extract. Lanes 2 to 5 show protein-DNA complexes
formed in the presence of extracts containing 7 Fg of protein from
uninfected NHF cells or from NHF cells harvested 12, 40, and 65
hpi, respectively; inf., infection. Lanes 6 to 8 show the binding site
specificity of the protein-DNA complexes formed in the presence of
the 40-hpi NHF cell extract; lane 6 contained no added oligonucle-
otide. Lane 7 shows competition with a 20-fold molar excess of the
wild-type (WT) DHFR E2F site oligonucleotide. Lane 8 shows
competition with a 20-fold molar excess of the double-site mutant
(dsmut) DHFR E2F site oligonucleotide. Lanes 9 and 10 show
protein-DNA complexes formed in the presence of extracts from
uninfected HEL cells or from HEL cells harvested 4 hpi. Free E2F
indicates the band representing the migration of free E2F bound to
DNA as previously characterized in experiments with extracts from
HeLa cells. The more slowly migrating infection-specific complex is
indicated by the arrowhead adjacent to lane 4 and in lane 10. The
complex that was formed in extracts from uninfected cells (lanes 2
and 9), that migrated between the position of free E2F and the
infection-specific complex, and that decreased in intensity upon
HCMV infection was further characterized (see Fig. 5). (B) Binding
in control gel mobility shift reactions to a probe containing the
recognition sequence for the adenovirus major late transcription
factor (MLTF). Gel mobility shift reactions in the presence of NHF
cell extracts were identical to those in the corresponding lanes in
panel A.
Two possibilities were immediately suggested by the
HCMV-induced binding to the DHFR E2F site. Either the
binding of another cellular or viral protein was induced by
infection and competed for free E2F binding or at least one
additional protein was associated with E2F. Treatment with
DOC, which disrupts protein-protein interactions at low
concentrations, was previously used to dissociate hetero-
meric E2F-containing complexes on the E2 promoter, elim-
inating the more slowly migrating complexes and leaving
only free E2F bound to the promoter (8, 65). We allowed
j J
FIG. 4. The infection-specific complex involves a protein-pro-
tein interaction that is dissociated by 12S ElA. (A) The DHFR E2F
site promoter fragment probe was incubated with extracts from
HCMV-infected HEL cells (4 hpi) in the absence or presence of
0.25% DOC. The infection-specific complex bound to the DHFR
E2F site promoter was disrupted, and free E2F remained bound to
the probe. In some experiments, DOC dissociation led to an
increase in free E2F binding activity. (B) A reticulocyte lysate
containing in vitro-translated wild-type or mutant (mut) 12S ElA
protein was added to a gel mobility shift reaction mixture. The
wild-type protein (lane 2) but not the mutated protein (lane 3)
dissociated the HCMV infection-specific complex, releasing free
E2F. The supershifted complex visible in lane 2 may represent the
binding of 12S ElA to one or more of the proteins in the infection-
specific complex. Lanes 4 and 5 show DNA binding activity in the
reticulocyte lysates.
HCMV infection-specific complexes to form on the DHFR
E2F site before adding DOC. The results of this experiment
are shown in Fig. 4A. DOC treatment eliminated the more
slowly migrating complex, suggesting that an infection-
specific protein-protein interaction involving E2F was dis-
rupted.
To further characterize the infection-specific complex, we
added a reticulocyte lysate expressing the 12S adenovirus
ElA protein to gel mobility shift reaction mixtures. The
wild-type ElA protein synthesized in this lysate does not
contain an amino-terminal activation domain (conserved
region 3) found in the 13S ElA product, but the two domains
(conserved regions 1 and 2) found in the 12S ElA product
have been shown to be sufficient to dissociate heteromeric
E2F complexes and release free E2F (73). In the experiment
shown in Fig. 4B, the 12S ElA-programmed lysate dissoci-
ated the infection-specific complex and increased the level of
free E2F binding to the DHFR E2F site in extracts from
HCMV-infected HEL cells, confirming that a protein-pro-
tein interaction involving E2F led to the infection-specific
complex. In addition, we sometimes observed a small
amount of a supershifted complex that may represent an
interaction between the 12S ElA gene product and one or
more of the components of the infection-specific complex. A
lysate containing an equal amount of a 12S ElA protein with
a single amino acid change resulting from a point mutation in
conserved region 2 had no effect on the infection-specific
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FIG. 5. The p107 protein is associated with E2F in distinct
complexes in uninfected cells and in both HCMV-infected and
S-phase cells. Complexes formed in extracts from mock-infected
(lane 1), HCMV-infected (lane 5), and S-phase (lane 9) HEL cells
are shown. Affinity-purified antibodies against p107 (lanes 2, 6, and
10) or p34cdc2 (lanes 3, 7, and 11) were added to gel mobility shift
reaction mixtures. The p107 antiserum reduced the intensity of the
most slowly migrating complex in each extract and produced a
supershifted complex, while neither the p34cdc2 control antibodies
nor a monoclonal antibody against Rb (lanes 4, 8, and 12) had an
effect on the complexes.
is shown in Fig. 4B, lanes 4 and 5. The lysates acted
identically on NHF cell infection-specific complexes (data
not shown).
These results, taken together, demonstrated that at the
level of E2F binding, the consequences of HCMV infection
were different from those associated with adenovirus infec-
tion. Indeed, HCMV infection led to the induction of a
heteromeric complex that could be dissociated by the aden-
ovirus ElA protein-a result that is supported by earlier
work showing that no infection-specific complex forms on
the DHFR E2F site during ElA activation of the DHFR
promoter (41). Our gel mobility shift experiments also
showed that the HCMV infection-specific complex was
identical on wild-type or mutant DHFR and E2 promoters as
long as a single E2F site was available for binding; in
contrast, the adenovirus infection-specific complex contain-
ing E2F and the viral E4 protein is dependent on the
presence of two properly spaced and oriented E2F sites and
is the only known heteromeric E2F-containing complex that
is not dissociated by ElA (37, 74).
Previous studies suggested several possibilities for the
identity of proteins in the HCMV infection-specific complex.
Because the complex required only a single E2F site, it
seemed unlikely that it was mediated by an activity analo-
gous to that of adenovirus E4, which stabilizes the cooper-
ative binding of two E2F molecules to adjacent sites on the
E2 promoter (6, 38, 49, 63, 68, 75, 76). However, the HCMV
IE 1 protein has been shown to associate with metaphase
chromosomes (57), and it was conceivable that this associ-
ation could be mediated by DNA-bound transcription fac-
tors. Alternatively, it was possible that the complex repre-
sented an interaction between E2F and a viral protein similar
to the hepatitis B virus X or herpes simplex virus VP16
protein, which can activate transcription by forming DNA
binding protein-protein complexes with cellular transcription
factors (33, 61). In several experiments, antibodies against
HCMV IE 1 and 2 gene products had no effect on the
infection-specific complex when added to gel mobility shift
reaction mixtures (data not shown).
Other possibilities for the identity of the infection-specific
complex were suggested by observations of cell cycle-
regulated E2F complexes, which initially were observed in
extracts from synchronized mouse BALB/c 3T3 cells (66)
and further characterized by a number of groups. Recent
studies showed, for example, that two nuclear pocket pro-
teins, Rb and p107, can interact with E2F in specific DNA
binding complexes. A DNA binding complex involving E2F
and the Gl-associated underphosphorylated form of Rb has
been characterized, and it has been suggested that this form
of E2F may exhibit a decreased ability to activate the
transcription of genes modulated by E2F (9, 11, 20, 21, 42).
Because it was possible that HCMV could disrupt an Rb-
E2F complex to activate DHFR, we asked whether Rb was
part of an E2F complex that was observed in uninfected cells
and that sometimes decreased in intensity upon HCMV
infection (Fig. 3, 5, and 6). This complex in uninfected cells,
like the infection-specific complex, was dissociated to free
E2F by treatment with either DOC or 12S ElA (data not
shown). An antibody previously shown to supershift or
eliminate E2F-Rb complexes failed to detect Rb in com-
plexes from late-log-phase uninfected HEL cells (Fig. 6, lane
4). This antibody also failed to detect Rb in either the
infection-specific complex or the S-phase complex (Fig. 6,
lanes 8 and 12), although it did detect Rb in a mid-log-phase
cell population (data not shown).
We then tested each of these cell extracts for the presence
of p107 (29), an Rb-related protein that previously had been
identified in S-phase E2F complexes (19, 24, 78). We de-
tected p107 in the complex that migrated more slowly than
free E2F in uninfected-cell extracts (Fig. 5, lane 2). An
E2F-p107 complex in Gl-phase cells also has been observed
by at least one other group (77). We also detected p107 in
both the HCMV infection-specific complex and the S-phase-
specific complex in extracts from HEL cells (Fig. 5, lanes 6
and 10), while neither control antibodies (Fig. 5, lanes 3, 7,
and 11) nor normal mouse serum (data not shown) had any
effect on the complexes.
Because the p107-containing complexes in S-phase and
HCMV-infected cells seemed to comigrate (Fig. 5), we
tested the infection-specific complex for the presence of
other known components of the S-phase complex. The
unexpected presence of the cell cycle regulatory cyclin A
protein (72) in an S-phase complex with E2F was first
demonstrated in 3T3 cells (65) and confirmed in other cell
types by several groups. The addition of an antiserum
against the cyclin A protein to gel mobility shift reaction
mixtures eliminated the HCMV infection-specific complex
(Fig. 6A, lanes 2 and 3), while neither affinity-purified
antibodies against cyclin B (lane 4) nor an antiserum against
p34cdc2 (lane 5) affected the complex. Figure 6A, lanes 6 to
10, confirms the presence of cyclin A in an S-phase extract
from HEL cells, and lanes 11 to 13 show controls in which
the cyclin A antiserum was tested against the complexes
found in extracts from mock-infected HEL cells. The pres-
ence of cyclin A in 40-hpi NHF cell extracts also was
confirmed (data not shown).
Another recently described component of S-phase E2F
complexes, cyclin A-associated p33c'2 (19, 24, 26, 78, 87),
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FIG. 6. The infection-specific complex contains cyclin A and p33cdk2. (A) Complexes formed in extracts from HCMV-infected (4-hpi) HEL
cells (lanes 1 to 5), S-phase HEL cells (lanes 6 to 10), or mock-infected HEL cells (lanes 11 to 13) are shown. Either 0.1 (lanes 2, 7, and 12)
or 0.5 (lanes 3, 8, and 13) p,l of cyclin A antiserum was added to gel mobility shift reaction mixtures before electrophoresis, eliminating cyclin
A-containing complexes in the HCMV-infected and S-phase extracts. As negative controls, gel mobility shift reaction mixtures were
incubated with 200 ng of affinity-purified antibodies against cyclin B (lanes 4 and 9) or 0.5 Al of a p34C&2 antiserum (lanes 5 and 10). The
reactions shown in lanes 1 to 13 were resolved on the same gel, but different exposures of each set of reactions are shown to visualize the
complexes more clearly. (B) Cyclin A-associated p33cdk2, but not p34cdc2, is part of the infection-specific complex. The indicated amounts of
antiserum against each kinase were added to gel mobility shift reaction mixtures. Only the p33cdk2 antiserum (lanes 5 to 7) interacted with the
infection-specific complex from HEL cells. The complex was decreased in intensity, and a supershifted complex appeared. The specificity
of the complexes was confirmed by competition with wild-type (E2F) or mutant (E2Fmut) E2F site oligonucleotides (lanes 8 and 9). The
increase in the intensity of E2F complexes produced by the addition of either antiserum or normal serum also has been observed by others
(e.g., 19) and may be caused by a stabilizing effect of serum proteins on E2F complexes.
was also shown to be part of the HCMV infection-specific
complex. A rabbit antiserum against p33cdk2 (69) effectively
supershifted the infection-specific complex (Fig. 6B). A
rabbit antiserum against another cell cycle-regulated kinase
that can associate with cyclin A, p34cdc, had no effect on the
infection-specific complex. In the experiment depicted in
Fig. 6B, the infection-specific complex tested was from 4-hpi
HEL cell extracts. As expected, anti-p33cdk2 antiserum also
interacted with the NHF cell infection-specific complex
(data not shown).
Taken together, the binding assays, dissociation experi-
ment, and immunological data identified common character-
istics and components for recently characterized S-phase
complexes involving the E2F transcription factor and the
HCMV infection-specific complexes that we had identified.
However, it was possible that there were differences be-
tween the infection-specific complexes and the S-phase
complexes that were not resolvable in these assays. To test
one possible difference-that the HCMV infection-specific
complexes changed the DNA base contact points with the
E2F binding site from those previously characterized for free
E2F (14) and an E2F- and cyclin A-containing complex from
mouse L cells (8)-we performed methylation interference
assays. Figure 7 shows that on either DNA strand, the
modified G residues that interfered with protein binding were
identical whether free E2F or the cyclin-containing com-
plexes from HCMV-infected NHF cells were examined.
This result was identical to that obtained when the L-cell
complex was examined for changes in G residue contacts (8).
A missing base contact assay in which T and C residues were
modified before protein was allowed to bind to the probes
also failed to detect differences in base interactions between
free E2F and E2F in the HCMV infection-specific complex
(data not shown).
DISCUSSION
This study shows that HCMV activates the promoter of
the cellular DHFR gene. Transcription factor E2F is a
mediator for HCMV activation of this promoter by HCMV
IE gene products. Also, we show that HCMV infection leads
to the induction of a heteromeric DNA binding complex
containing E2F, p107, cyclin A, and p33cdk2. This complex is
similar and possibly identical to a complex previously shown
to be characteristic of cells that are in the S phase of the cell
cycle (19, 24, 65, 69). These results, therefore, are consistent
with earlier findings that suggest that HCMV induces DNA
synthesis (2, 4, 5, 23, 32, 81, 82), although we have not
established a temporal correlation between the induction of
the E2F-p107-cyclin A_p33Cdk2 complex and any infection-
induced entry of cells into the S phase. The functional role of
E2F- and cyclin A-containing complexes has not been dem-
onstrated, and their role may relate to replication, transcrip-
tion, or even some link between these cellular processes.
Earlier studies showed that several other cellular genes
necessary for proliferation or DNA replication are induced
by HCMV infection. These include those for DNA polymer-
ase a (44, 46), thymidine kinase (27, 90), omithine decarbox-
ylase (50), and topoisomerase II (13). The activation of
DHFR, which is required for DNA replication, is therefore
consistent with this pattern of gene activation by the virus.













FIG. 7. Methylation interference analysis of the E2F complexes.
Methylation of G residues has an identical effect on the binding of
free E2F or of a E2F- and cyclin A-containing complex. The top (A)
or bottom (B) strand of a DHFR wild-type promoter fragment
containing the E2F site was specifically end labeled and partially
methylated at G residues with dimethyl sulfate before being added to
scaled-up gel mobility shift reaction mixtures. Bands representing
the free probe (free), probe bound to free E2F (E2F), or probe
bound to the E2F-cyclin A complex (E2F/cyclin A) were excised
from the gel, purified, and cleaved with piperidine before electro-
phoresis through a denaturing gel. Lane G is a G ladder that
confirms the positions of G residues in the promoter sequence.
Asterisks show G residues that interfere with protein bonding.
strate that E2F is required for maximal HCMV activation of
the DHFR promoter by products of the HCMV IE 1 and 2
genes. The promoters of at least three HCMV early genes
contain potential E2F sites. One of these genes produces a
2.2-kb transcript encoding several proteins by differential
splicing, another results in the production of a 2.7-kb mRNA
species, and a third is termed UL 84 (47, 54, 55, 80, 88). At
least two other cellular genes activated by HCMV, those for
DNA polymerase a (71) and c-myc (86), have E2F sites in
functionally important regions of their respective promoters.
It is important to point out that, like ElA and several other
viral immediate early proteins, the HCMV IE gene products
are promiscuous trans-activators and can modulate tran-
scription from many promoters that do not contain E2F
sites. Additionally, all E2F-containing promoters character-
ized to date contain binding sites for other transcription
factors that may be activated by IE gene products; indeed,
we have found that E2F dependence may be affected by
factors such as the growth state of cells and that major IE
gene products expressed at high levels can provide some
activation of the E2F double-site mutant DHFR promoter,
possibly through the Spl binding sites (data not shown).
Nevertheless, we have also shown that a synthetic promoter
construct consisting only of a TATA element and a single
upstream E2F site can be activated by the HCMV IE 1 and
2 gene products (51), and we suggest that activation through
E2F sites by an HCMV IE protein(s) can play an important
role in productive HCMV infection. It has been reported that
HCMV IE 2, but not IE 1, can interact directly with and
activate transcription through the TATA binding factor
TFIID (36), and it is likely that there are distinct interactions
among the various IE region gene products and specific
transcription factors or components of the general transcrip-
tional machinery.
Infection-induced complexes. The induction of infection-
specific complex formation may simply be the result of the
ability of HCMV to induce cellular DNA synthesis. How-
ever, our data demonstrate that at the molecular level, the
effect of HCMV infection on interactions among several cell
cycle-regulated proteins bound via E2F to a cellular pro-
moter is different from the effect of adenovirus infection,
even though both viruses activate the transcription of many
of the same cellular genes and induce cellular DNA synthe-
sis. It is clear that many important questions-including
determination of the functional role of the E2F-p107-cyclin
A-p33cd2 complex during the cell cycle and during viral
infection-require more study. E2F recently has been
cloned independently by two groups on the basis of its ability
to bind directly to Rb (39, 52), allowing experiments to
address these questions more directly.
It will also be important to determine whether the expres-
sion of products of the HCMV major IE genes is sufficient
both for the formation of the infection-specific complex and
for the decrease in intensity of the E2F-p1O7 complex
observed in uninfected cells. It has been suggested that a
variety of physiological effects of HCMV infection which
resemble the responses of cells to growth factors occur
independently of IE gene expression and may be due to
signal pathways induced by the binding of the virus particle
to the cell (2, 3). Although our results show that E2F is
involved in the activation of the DHFR promoter by HCMV
IE gene products, it is possible that the formation of the
E2F-p107-cyclin A-p33c 2 complex is related to an HCMV-
induced signal pathway that is independent of IE gene
expression and its effect on DHFR expression. It is also
possible that HCMV IE proteins interact directly with one or
more components of the E2F complexes. Adenovirus ElA
protein has been shown to bind directly to p33Cdk2, cyclin A,
p107, Rb, and other cellular proteins, some of which also
bind directly to one another and to E2F (e.g., 19, 28, 30, 87).
The HCMV IE 2 protein also interacts directly with a
number of cellular proteins, and these interactions may be
functionally analogous to those between ElA and cellular
proteins (31).
Recent work has shown that HCMV induces the expres-
sion of the cellular proto-oncogenes myc, fos, and jun, with
kinetics slightly different from those induced by serum
(16-18). Furthermore, it has long been known that HCMV
perturbs the cell cycle and can lead to chromosome damage
(1, 53, 60, 67). A careful comparison ofE2F complex binding
during HCMV infection and the normal cell cycle could
provide clues about possible mechanisms for these effects
and for the function of E2F complexes. We are attempting to
determine whether the temporal differences in the induction
of complex formation that we observed between HEL and
NHF cells relate to subtle differences between the cell types
or the condition of the cells at the time of HCMV infection or
to other factors. These differences, as well as the ability to
study synchronized growing fibroblasts, should allow for
temporal comparisons among complex formation, the initia-
tion of cellular DNA synthesis, and transcriptional induction
of genes modulated by E2F. Therefore, complexes induced
by HCMV infection could be useful in determining a func-
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anchored to gene promoters during the S phase and, as we
have now shown, during HCMV infection.
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